ReviewJournal of clinical medicine2019
Gastrointestinal Microbiota and Type 1 Diabetes Mellitus: The State of Art.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- The effect of oral probiotics on glycated haemoglobin levels in children with type 1 diabetes mellitus - a randomized clinical trial.Pediatric endocrinology, diabetes, and metabolism · 2023Trial
- Ananalysis of the effects of Treg cell therapy intervention on the gut microbiota of type 1 diabetic mice using 16S rRNA gene sequencing.Experimental biology and medicine (Maywood, N.J.) · 2026Article
- Review
- Serum Zonulin and Lipopolysaccharide (LPS) Levels in Early Myocardial Infarction: Association with Left Ventricular Ejection Fraction.Journal of clinical medicine · 2025Article
- Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future.Biomolecules & biomedicine · 2025Review
- Health-Improving Effects of Polyphenols on the Human Intestinal Microbiota: A Review.International journal of molecular sciences · 2025Review
- Beneficial In Vitro Effects of Polysaccharide and Non-Polysaccharide Components ofMolecules (Basel, Switzerland) · 2024Article
- Characterization of the gut bacterial and viral microbiota in latent autoimmune diabetes in adults.Scientific reports · 2024Article
- Elevated Serum IgA at Onset of Type 1 Diabetes in Children.Pediatric diabetes · 2024Article
- The Role of the Adrenal-Gut-Brain Axis on Comorbid Depressive Disorder Development in Diabetes.Biomolecules · 2023Review
- Microbiota revolution: How gut microbes regulate our lives.World journal of gastroenterology · 2023Review
- Nicotinamide Riboside Improves Enteric Neuropathy in Streptozocin-Induced Diabetic Rats Through Myenteric Plexus Neuroprotection.Digestive diseases and sciences · 2023Article
- Review
- Allergy and autoimmunity in children: non-mutually exclusive diseases. A narrative review.Frontiers in pediatrics · 2023Review
- Impact of gut-peripheral nervous system axis on the development of diabetic neuropathy.Memorias do Instituto Oswaldo Cruz · 2023Article
- Evidence Suggesting the Role of Gut Dysbiosis in Diabetic Retinopathy.Investigative ophthalmology & visual science · 2022Review
- The Role of Nutritional Factors in the Modulation of the Composition of the Gut Microbiota in People with Autoimmune Diabetes.Nutrients · 2022Review
- Environmental Factors and the Risk of Developing Type 1 Diabetes-Old Disease and New Data.Biology · 2022Review
- Intestinal 'Infant-Type' Bifidobacteria Mediate Immune System Development in the First 1000 Days of Life.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of autoimmune type 1 diabetes (T1DM) is increasing worldwide and disease onset tends to occur at a younger age. Unfortunately, clinical trials aiming to detect predictive factors of disease, in individuals with a high risk of T1DM, reported negative results. Hence, actually there are no tools or strategies to prevent T1DM onset. The importance of the gut microbiome in autoimmune diseases is increasingly recognized and recent data suggest that intestinal dysbiosis has a pathogenic role in T1DM by affecting both intestinal immunostasis and the permeability of the gut barrier. An improved understanding of the mechanisms whereby dysbiosis in the gut favors T1DM development may help develop new intervention strategies to reduce both the incidence and burden of T1DM. This review summarizes available data on the associations between gut microbiota and T1DM in both experimental animals and humans and discusses future perspectives in this novel and exciting area of research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.